No clinically important response to treatment ‐ short term · patients with schizophrenia
It is very uncertain whether BENZODIAZEPINES changes no clinically important response to treatment ‐ short term compared with ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Global state: not improved ‐ short‐term GAF · schizophrenia
Technology‐mediated psychoeducation + standard care intervention showed no clear difference in global state: not improved ‐ short‐term GAF compared with standard care intervention (low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · schizophrenia
Technology‐mediated psychoeducation showed no clear difference in mental state: not improved ‐ short‐term BPRS compared with standard care intervention (low certainty).
1 finding from 1 review
Global state: not improved ‐ short‐term GAF · schizophrenia
Technology‐mediated psychoeducation showed no clear difference in global state: not improved ‐ short‐term GAF compared with standard care intervention (low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · schizophrenia
Technology‐mediated psychoeducation + standard care intervention showed no clear difference in mental state: not improved ‐ short‐term BPRS compared with standard care intervention (low certainty).
1 finding from 1 review
Intervention not reported
Leaving the study early ‐ Adverse event: Short‐term · schizophrenia
The intervention showed no clear difference in leaving the study early ‐ Adverse event: Short‐term; GRADE not reported.
1 finding from 1 review
Intervention not reported
Cognitive function: 3. Short‐term ‐ Average end point score on various subscales of WAIS III (high = favourable) ‐ Digit symbol score · schizophrenia
1 finding from 1 review
Intervention not reported
Cognitive function: 4. Short‐term ‐ Average end point score on various subscales of HVLT (high = favourable) ‐ Recognition · schizophrenia
1 finding from 1 review
Intervention not reported
Adverse event: 11a. Short‐term ‐ Average end point score on EPSEs scale (low = favourable) ‐ AIMS · schizophrenia
1 finding from 1 review
Intervention not reported
Quality of life ‐ Physical health domain SF‐36 Short form · patients with type 1 diabetes mellitus
1 finding from 1 review
Intervention not reported
Quality of life ‐ Mental health domain SF‐36 Short form · patients with type 1 diabetes mellitus
1 finding from 1 review
Dyspnoea during exercise Modified Borg dyspnoea score at end of 6‐minute walk test Scores range from 0 to 10, with lower scores indicating less shortness of breath · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Dyspnoea during exercise Modified Borg dyspnoea score at end of 6‐minute walk test Scores range from 0 to 10, with lower scores indicating less shortness of breath · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Dyspnea · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Dyspnoea during treadmill walking Borg scale at isotime during constant work rate treadmill test Scale ranges from 0 to 10, with lower scores indicating less shortness of breath · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Change in dyspnoea score · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Health‐related quality of life (Change in CRQ Dyspnoea) CRQ · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Dyspnea · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Health‐related quality of life Dyspnoea domain of Hiratsuka scale Scores range from 0 to 100, with lower scores indicating less shortness of breath · patients with chronic obstructive pulmonary disease
1 finding from 1 review
Pain at present McGill short form questionnaire ‐ Verbal rating scale (0‐5) · patients with pain management in rheumatoid arthritis
1 finding from 1 review